High materiality7/10
Nuvectis Pharma price target raised to $33 from $20 at Roth Capital
Why it may matterVerify against the original reporting
Upside potential from analyst price target update.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Analyst target update indicates upside potential for NVCT; target raised to $33 from $20; current price $19.57.
- Target raised to $33 from $20; current price $19.57; implied upside.
Key facts
- 01
Target: $33
- 02
Posted price: $19.57
- 03
Analyst firm: UBS
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.